India's $16B MedTech Market Targets $600B Global Hub at Delhi Event
At the 9th India Medical Device 2026 conference, policymakers underscored the shift from import reliance to domestic manufacturing to improve healthcare access and device quality. A white paper on service and maintenance was released, signaling a holistic approach to the device lifecycle.
Key Takeaways
- At the 9th India Medical Device 2026 conference, policymakers underscored the shift from import reliance to domestic manufacturing to improve healthcare access and device quality.
- A white paper on service and maintenance was released, signaling a holistic approach to the device lifecycle.
Mentioned
Key Intelligence
Key Facts
- 1India's medical device market is valued at $16 billion, compared to a global market of $600 billion, as stated by Secretary Manoj Joshi.
- 2The 9th India Medical Device 2026 conference (August 7–8) is organized by the Department of Pharmaceuticals and FICCI under the theme 'Towards Viksit Bharat: Advancing India as a Global Hub for Quality Medical Devices'.
- 3A white paper on strengthening medical equipment service and maintenance was released at the inaugural session.
- 4DCGI Rajeev Singh Raghuvanshi called for a shift from an import-driven model to domestic manufacturing-led growth.
- 5India has made significant progress in manufacturing consumables, disposables, and in assembling high-end equipment including diagnostics and imaging systems.
- 6The conference aims to position India as a reliable global hub for quality medical devices, leveraging both healthcare and industrial policy perspectives.
The medical devices sector needs to be viewed from both a healthcare and industry perspective. While healthcare providers focus on access to quality devices irrespective of their origin, domestic manufacturing is critical for generating employment, strengthening industry capabilities, and ensuring supply chain resilience, especially during global disruptions.
Inaugural address at 9th India Medical Device 2026
Highlighted by Secretary Joshi at conference opening
Analysis
For healthcare providers, hospital administrators, and health IT leaders, India’s $16 billion medical device market—still heavily dependent on imports—has always meant premium pricing and fragile supply chains. The policies and partnerships discussed at this week’s Delhi conference could reshape procurement landscapes, making higher-quality diagnostics and imaging equipment more affordable and accessible across the country.
The 9th India Medical Device 2026 conference opened on August 7, 2026, at Vigyan Bhawan in New Delhi, signaling a concerted push by the Indian government and industry to transform the country into a global hub for medical device manufacturing. Organized by the Department of Pharmaceuticals and the Federation of Indian Chambers of Commerce and Industry (FICCI), the two-day event convened policymakers, regulators, innovators, and business leaders under the theme ‘Towards Viksit Bharat: Advancing India as a Global Hub for Quality Medical Devices’.
Manoj Joshi, Secretary of the Department of Pharmaceuticals, highlighted that India’s medical device market currently stands at $16 billion, a fraction of the $600 billion global market.
The inaugural session laid out the scale of the opportunity. Manoj Joshi, Secretary of the Department of Pharmaceuticals, highlighted that India’s medical device market currently stands at $16 billion, a fraction of the $600 billion global market. He emphasized that the sector must be viewed through both a healthcare and an industry lens: while healthcare providers prioritize access to quality devices regardless of provenance, domestic manufacturing is essential for employment, industrial capability, and supply-chain resilience—lessons underscored by recent global disruptions. This dual framing reflects a maturation in Indian policy thinking, acknowledging that import dependence not only strains healthcare budgets but also exposes the country to strategic vulnerabilities.
Joshi noted tangible progress in local production, particularly in consumables, disposables, and the assembly of high-end equipment such as diagnostics and imaging systems. However, he stressed the need to deepen domestic value addition by strengthening component manufacturing, encouraging innovation in advanced medical technologies, and continuously raising quality standards. These remarks signal a shift from simple assembly operations to a more integrated, R&D-intensive ecosystem.
The regulatory dimension was addressed by Rajeev Singh Raghuvanshi, the Drug Controller General of India (DCGI), who called for a transformation from an import-driven model to one led by domestic manufacturing. Such statements from the country’s top devices regulator indicate that future policy may include streamlined approvals, quality benchmarks aligned with international norms, and production-linked incentive schemes that have already proven effective in other sectors. For industry participants, this would reduce uncertainty and unlock investment.
A white paper on strengthening medical equipment service and maintenance was released during the inaugural session. This often-overlooked aspect of the device lifecycle is critical for both patient safety and total cost of ownership. By addressing after-sales support, the government acknowledges that lowering dependency on foreign original equipment manufacturers for maintenance can further boost confidence in locally produced devices and make them more attractive to both domestic and export markets.
The conference theme aligns with India’s broader ambition of becoming a developed nation by 2047 (‘Viksit Bharat’). The medical device sector is seen as a high-growth, high-value industry that can create jobs, reduce the trade deficit in healthcare products, and position India as a reliable alternative to China in global supply chains. With the world’s second-largest population and a growing middle class, the domestic market alone provides a testing ground for scale, while exports to other emerging economies in Asia, Africa, and Latin America represent a sizable opportunity.
What to Watch
From an industry perspective, the conference is a platform for deal-making and knowledge sharing. FICCI’s involvement brings private-sector heft, and the presence of innovators suggests that start-ups in wearables, point-of-care diagnostics, and AI-driven imaging could find policy support and funding. The emphasis on quality standards and service infrastructure also points to opportunities for health IT companies that can integrate device data with hospital information systems, aligning with the government’s digital health mission.
Looking ahead, the success of this initiative will depend on execution. India must navigate complex regulatory harmonization with major markets like the US FDA and EU MDR to enable exports. It will need to build a skilled workforce for R&D and manufacturing. And it must ensure that domestic production translates into lower costs and better care at the grassroots level, not just industrial growth. The white paper and the Secretary’s remarks suggest a holistic approach, but the real test will be in translating conference rhetoric into concrete timelines and measurable outcomes. For now, India Medical Device 2026 has put a clear stake in the ground: the country intends to be not just a consumer but a net producer of quality medical technology on the world stage.
Sources
Sources
Based on 2 source articles- newkerala.comIndia Medical Device 2026 : Global MedTech Hub PushAug 7, 2026
- aninews.in9th India Medical Device 2026 kicks off in Delhi ; focus on building India as a Global MedTech HubAug 7, 2026
Cite This Page
"India's $16B MedTech Market Targets $600B Global Hub at Delhi Event." Healthcare Intelligence Brief, August 7, 2026. https://gethealthbrief.com/story/india-medtech-hub-2026-healthcare-impact
How we covered this story
Every story in our healthcare coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the healthcare space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
Sources are only linked to a story once they clear our classification pipeline at a minimum 35 percent relevance threshold. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong in this story — a wrong fact, a broken source link, a misattributed entity? Report a data issue.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled healthcare-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |